busted.produk
Bluelighter
- Joined
- Jul 12, 2015
- Messages
- 289
So im lurkin online, lookin to see if there's any new scholarly articles or research related to mytragynine, 7-OH mytragynine, etc and i stumble onto this pharma company's website(which has nothing to do with kratom, that i can see), trevena inc.
It looks like they're developing some new safer(supposedly) opioids. They are in phase III of one, TRV130(olceridine), that according to them looks pretty promising.
Here's a short excerpt from one of their papers:
"TRV130 is a G-protein-biased ligand of the m-opioid receptor:
It produces G protein activation with little b-arrestin recruitment,
presumably by changing the conformation of the m-opioid
receptor when it binds, resulting in lessened b-arrestin re-
cruitment, as has been observed in peptides that modulate other
G-protein-coupled receptors. TRV130 has demonstrated
potent analgesia and a differentiated tolerability profile in pre-
clinical models, including less constipation and respiratory
depression at equianalgesic doses(to morphine)"
I don't yet have an opinion about them(cause im still reading in another tab) but i figured it's worth bringing to yalls attention since it caught my eye.
Here's a link http://www.trevena.com/ to their site.
Shit, they must at least be on the right track since they're in phase III of trials. Their other two drugs aren't as far along(phase I and pre-clinical whatever of another) but who knows, TRV130 might be the "next big thing".
It looks like they're developing some new safer(supposedly) opioids. They are in phase III of one, TRV130(olceridine), that according to them looks pretty promising.
Here's a short excerpt from one of their papers:
"TRV130 is a G-protein-biased ligand of the m-opioid receptor:
It produces G protein activation with little b-arrestin recruitment,
presumably by changing the conformation of the m-opioid
receptor when it binds, resulting in lessened b-arrestin re-
cruitment, as has been observed in peptides that modulate other
G-protein-coupled receptors. TRV130 has demonstrated
potent analgesia and a differentiated tolerability profile in pre-
clinical models, including less constipation and respiratory
depression at equianalgesic doses(to morphine)"
I don't yet have an opinion about them(cause im still reading in another tab) but i figured it's worth bringing to yalls attention since it caught my eye.
Here's a link http://www.trevena.com/ to their site.
Shit, they must at least be on the right track since they're in phase III of trials. Their other two drugs aren't as far along(phase I and pre-clinical whatever of another) but who knows, TRV130 might be the "next big thing".
Last edited: